Reply to "Innovation and off-label use, the French case and more" by Braillon and Lexchin.

导出 OA

翻译打印收藏纠错

第一作者： Jan,Borysowski

第一单位： Centre for Studies on Research Integrity, Institute of Law Studies, Polish Academy of Sciences, Warsaw, Poland.;Department of Clinical Immunology, Medical University of Warsaw, Warsaw, Poland.

作者： Jan,Borysowski ^[1] ; Hans-Jörg,Ehni ^[2] ; Andrzej,Górski ^[3]

作者单位： Centre for Studies on Research Integrity, Institute of Law Studies, Polish Academy of Sciences, Warsaw, Poland.;Department of Clinical Immunology, Medical University of Warsaw, Warsaw, Poland. ^[1] Institute of Ethics and History of Medicine, Eberhard Karls Universität, Tübingen, Germany. ^[2] Department of Clinical Immunology, Medical University of Warsaw, Warsaw, Poland.;Laboratory of Bacteriophages, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland. ^[3]

关键词 evidence-based medicine medication safety pharmacotherapy therapeutics

主题词伦理准则(Codes of Ethics);药品标示外使用(Off-Label Use)

DOI 10.1111/bcp.14068

PMID 31410871

发布时间 2024-07-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交